Janssen to open three new research platforms

US health care giant Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen is to launch three new research platforms focused on disease prevention, disease interception, and the microbiome.

The new teams will work with Janssen’s therapeutic areas and external partners to underpin ongoing research and promote new scientific knowledge in these areas.

William Hait, global head of Janssen research and development, said: "The future of health care will increasingly depend on identifying and correctly interpreting the earliest signals of disease susceptibility, preventing or intercepting disease before it even begins, and using the latest scientific insights from promising, emerging fields like the microbiome, to transform medicine. By advancing science in these areas, our new research platforms will strive to deliver the next generation of transformational medical innovation.  We believe the positive impact on people, communities, governments, medicine and the global economy will be dramatic and far-reaching."